Figure 1
Figure 1. Cumulative incidence of neutrophil/platelet recovery and survival for 386 CBT cases. ab-negative indicates patient does not have anti-HLA antibody; ab-positive, patient has anti-HLA antibody but the CB does not have the corresponding antigen for the antibody specificity; and positive-vs-CB, patient has anti-HLA antibody and the CB has the corresponding antigen for the antibody specificity. The cumulative incidences of neutrophil recovery (A) for the ab-negative, ab-positive and positive-vs-CB groups were 83% (95% CI, 79%-87%), 73% (95% CI, 61%-82%), and 32% (95% CI, 13%-53%), respectively, at day 60 (P < .0001). The cumulative incidence for the ab-positive group was significantly lower than that of the ab-negative group (P = .024). The cumulative incidence for the positive-vs-CB group was significantly lower than that of the ab-positive group (P = .005). The cumulative incidences of platelet recovery (B) for the ab-negative, ab-positive and positive-vs-CB groups were 72% (95% CI, 67%-77%), 60% (95% CI, 47%-71%), and 33% (95% CI, 14%-55%), respectively, at 9 months (P = .0036). The differences between the ab-negative and ab-positive groups (P = .05) and the ab-positive and positive-vs-CB groups (P = .062) were not significant. For the Kaplan-Meier estimate of event-free survival (EFS; C), the impact of anti-HLA antibodies was significant (P = .0001), with EFS at 2 years for the ab-negative, ab-positive and positive-vs-CB groups being 43% (95% CI, 37%-49%), 29% (95% CI, 17%-41%), and 15% (95% CI, 4%-33%), respectively. The differences between the ab-negative and ab-positive groups (P = .037) and the ab-positive and positive-vs-CB groups (P = .016) were significant. For overall survival (OS; D), the impact of anti-HLA antibodies was significant (P = .030) with the OS at 2 years for the ab-negative, ab-positive and positive-vs-CB groups being 57% (95% CI, 51%-63%), 50% (95% CI, 36%-63%), and 31% (95% CI, 10%-55%), respectively. The differences between the ab-negative and ab-positive (P = .25) and the ab-positive and positive-vs-CB groups (P = .13) were not significant.

Cumulative incidence of neutrophil/platelet recovery and survival for 386 CBT cases. ab-negative indicates patient does not have anti-HLA antibody; ab-positive, patient has anti-HLA antibody but the CB does not have the corresponding antigen for the antibody specificity; and positive-vs-CB, patient has anti-HLA antibody and the CB has the corresponding antigen for the antibody specificity. The cumulative incidences of neutrophil recovery (A) for the ab-negative, ab-positive and positive-vs-CB groups were 83% (95% CI, 79%-87%), 73% (95% CI, 61%-82%), and 32% (95% CI, 13%-53%), respectively, at day 60 (P < .0001). The cumulative incidence for the ab-positive group was significantly lower than that of the ab-negative group (P = .024). The cumulative incidence for the positive-vs-CB group was significantly lower than that of the ab-positive group (P = .005). The cumulative incidences of platelet recovery (B) for the ab-negative, ab-positive and positive-vs-CB groups were 72% (95% CI, 67%-77%), 60% (95% CI, 47%-71%), and 33% (95% CI, 14%-55%), respectively, at 9 months (P = .0036). The differences between the ab-negative and ab-positive groups (P = .05) and the ab-positive and positive-vs-CB groups (P = .062) were not significant. For the Kaplan-Meier estimate of event-free survival (EFS; C), the impact of anti-HLA antibodies was significant (P = .0001), with EFS at 2 years for the ab-negative, ab-positive and positive-vs-CB groups being 43% (95% CI, 37%-49%), 29% (95% CI, 17%-41%), and 15% (95% CI, 4%-33%), respectively. The differences between the ab-negative and ab-positive groups (P = .037) and the ab-positive and positive-vs-CB groups (P = .016) were significant. For overall survival (OS; D), the impact of anti-HLA antibodies was significant (P = .030) with the OS at 2 years for the ab-negative, ab-positive and positive-vs-CB groups being 57% (95% CI, 51%-63%), 50% (95% CI, 36%-63%), and 31% (95% CI, 10%-55%), respectively. The differences between the ab-negative and ab-positive (P = .25) and the ab-positive and positive-vs-CB groups (P = .13) were not significant.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal